Eli Lilly has reported positive results from a late-stage trial showcasing the efficacy of its GLP-1 pill in aiding overweight adults with type 2 diabetes to achieve a weight loss of 10.5%. This milestone comes on the heels of a recent study on the same drug in non-diabetic patients, which had initially caused a decline in the company’s stock value. Following this announcement, shares of Eli Lilly surged by 2.4% to $712 in premarket trading.
The oral GLP-1 pill demonstrated substantial weight loss benefits, with 75% of patients receiving the highest dose of orforglipron achieving an A1C level at or below 6.5%. This result is particularly noteworthy as it falls below the target set by the American Diabetes Association for most adults. Orforglipron, being a small-molecule pill, offers advantages in terms of ease of manufacturing and packaging compared to injectable drugs currently popular for obesity treatment, such as Zepbound and Wegovy.
In a comprehensive 72-week study involving over 1,600 overweight or obese adults with type 2 diabetes, patients on the highest 36-milligram dose of orforglipron experienced a weight loss of 10.5%, while those on the lowest 6 mg dose lost 5.5% of their weight. This trial not only met its primary endpoint but also positioned Eli Lilly to pursue regulatory approvals for orforglipron. The company is considering various strategies, including the potential utilization of a priority review voucher to expedite the FDA approval process.
Eli Lilly views the oral GLP-1 pill as a significant breakthrough in providing a viable alternative to injections for diabetes and obesity management. The recent trial results not only demonstrated promising weight loss effects but also indicated improvements in heart-risk markers such as cholesterol, triglycerides, and blood pressure across all dosage levels. These findings bode well for potential future approvals and market penetration for orforglipron.
Despite the positive outcomes observed in the trial, concerns regarding side effects, particularly nausea and vomiting, have been noted. The high-dose patients in the study reported a nausea rate of 36.4% and a vomiting rate of 23.1%, leading to some patients discontinuing the trial due to adverse effects. However, the absence of liver safety issues is a reassuring factor highlighted by Eli Lilly.
The weight-loss market, estimated to reach $150 billion annually by the early 2030s, presents a lucrative opportunity for innovative treatments like orforglipron. As competitors like Wegovy aim for FDA approval for oral formulations, Eli Lilly’s advancements in GLP-1 oral therapy position the company favorably in a rapidly evolving landscape. Additionally, the potential for heart disease approvals could further enhance the market potential and insurance coverage prospects for weight-loss medications.
- Eli Lilly’s GLP-1 oral pill demonstrated significant weight loss of 10.5% in overweight adults with type 2 diabetes.
- Positive trial results positioned the company to pursue regulatory approvals for orforglipron, offering a promising alternative to injectable treatments.
- Side effects such as nausea and vomiting were noted in the trial, impacting some high-dose patients.
- Potential heart-risk marker improvements and future FDA approvals could enhance market penetration and insurance coverage for weight-loss drugs.
Read more on usatoday.com